Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

Martín, Miguel; Romero, Atocha; Cheang, Maggie C.U.; García-Asenjo, José Antonio López; García-Sáenz, José Á.; Oliva, Belén; Román, José Marı́a; He, Xiaping; Casado, Antonio; Torre, J. de la; Furio, V.; Puente, Javier; Caldés, Trinidad; Vidart, José Antonio; López-Tarruella, Sara; Díaz-Rubio, Eduardo; Perou, Charles M.

doi:10.1007/s10549-011-1461-y

Cited by 67 publications

(39 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A hypothesis-generating study indicated that TNBC/basal-like breast cancer had a poorer response to anthracycline-based therapy compared with other breast cancer subtypes [59]. The results of this study were laterally validated through this meta-analysis, which indicated that the anthracycline-based group had the lowest pCR.…”

Section: Discussionmentioning

confidence: 56%

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

Yang¹,

Liu

et al. 2014

World J Surg Onc

View full text Add to dashboard Cite

BackgroundTriple-negative breast cancer (TNBC) is a special subtype of breast cancer that is characterized by poor prognosis, strong tumor invasion and a high pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC). The pCR rate is a prognostic factor for TNBC. We aimed to evaluate the relationship between pCR and TNBC after NAC and originally tried to identify factors related to achieving pCR for TNBC using a meta-analysis.MethodsWe systematically searched the literature for pCR and breast cancer after NAC and carefully identified eligibility criteria. The association between pCR and breast cancer subtypes was estimated using Review Manager, while pCR rates for TNBC and non-TNBC were determined using Meta-Analyst.ResultsThis analysis included a total of 9,460 cases from 27 studies. The summary odds ratio estimating the relationship between pCR and breast cancer subtypes (TNBC vs non-TNBC) was 3.02 (95% confidence interval (CI), 2.66 to 3.42). The TNBC pCR rate was 28.9% (95% CI, 27.0 to 30.8%) and the non-TNBC was 12.5% (95% CI, 11.7 to 13.4%). From subgroup analyses, we identified the factors associated with the highest pCR rates for TNBC.ConclusionsTNBC has a higher pCR rate than non-TNBC. In the NAC setting, these factors of platinum-containing, more than six cycles, four kinds of drugs, 16 weeks’ treatment duration and sequential chemotherapy may contribute to increasing the pCR rate.

show abstract

Section: Discussionmentioning

confidence: 56%

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

Yang¹,

Liu

et al. 2014

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…In addition, several biomarkers and intrinsic subtypes have been reported as predictors of the neoadjuvant response (20,21). However, no basis for selecting the optimal chemotherapy for individual patients has been determined, and the association between the expression of topoisomerase Ⅱα and the different subtypes remains to be elucidated.…”

Section: Triple-negative Breast Cancer Exhibits a Favorable Response mentioning

confidence: 99%

Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα

Nogi

Uchida

Kamio

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The present study retrospectively analyzed the utility of topoisomerase Ⅱα expression as a prognostic marker to predict the neoadjuvant chemotherapeutic response and survival among different breast cancer subtypes. The patients were subtyped and the expression of topoisomerase Ⅱα was determined using immunohistochemistry. All patients (n=147) received an anthracycline-containing regimen preoperatively, and 139 (95%) patients also received docetaxel. Of the 147 patients, 25 (17%) were triple-negative and 20 (17%) were human epidermal growth factor receptor 2 (HER2)-positive. Among these subtypes, a significantly higher a rate (P<0.0001) and higher incidence of topoisomerase Ⅱα expression (P=0.036) were observed compared with that in the hormone receptor-positive and HER2-negative breast cancer types. However, the expression of topoisomerase Ⅱα revealed no correlation with the treatment response or survival in any of the subtypes. Therefore, these results indicated that the favorable response to anthracycline-containing chemotherapy among triple-negative and HER2-positive breast cancer was independent of the expression of topoisomerase Ⅱα.

show abstract

“…The five major molecular subtypes identified in these studies differ not only in regard to their pattern of gene expression and clinical features but also in regard to the response to treatment and clinical outcome [5,6,20,29,30]. Patients with luminal tumors respond well to endocrine therapy; however, luminal A and luminal B tumors respond differently to the type of endocrine agent used (tamoxifen or aromatase inhibitors) and also exhibit a variable response to chemotherapy [31][32][33][34].…”

Section: Molecular Classification: the Gene Expression ''Intrinsic'' mentioning

confidence: 99%

Molecular Classification and Prognostic Signatures of Breast Tumors

Cavalli

2013

Oncoplastic and Reconstructive Breast Surgery

View full text Add to dashboard Cite

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

Cited by 67 publications

References 64 publications

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα

Molecular Classification and Prognostic Signatures of Breast Tumors

Contact Info

Product

Resources

About